151 related articles for article (PubMed ID: 33047337)
21. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
22. Whey Protein Supplementation Improves the Glycemic Response and May Reduce Non-Alcoholic Fatty Liver Disease Related Biomarkers in Women with Polycystic Ovary Syndrome (PCOS).
Zumbro EL; Rao M; Balcom-Luker S; Broughton KS; LeMieux MJ
Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371959
[TBL] [Abstract][Full Text] [Related]
23. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease.
Salva-Pastor N; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
J Steroid Biochem Mol Biol; 2019 Nov; 194():105445. PubMed ID: 31381969
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens.
Gutierrez-Grobe Y; Ponciano-Rodríguez G; Ramos MH; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2010; 9(4):402-9. PubMed ID: 21057159
[TBL] [Abstract][Full Text] [Related]
25. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
27. [Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease].
Ciotta L; Pagano I; Stracquadanio M; Formuso C
Minerva Ginecol; 2011 Oct; 63(5):429-37. PubMed ID: 21926952
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
Kahal H; Abouda G; Rigby AS; Coady AM; Kilpatrick ES; Atkin SL
Clin Endocrinol (Oxf); 2014 Oct; 81(4):523-8. PubMed ID: 24256515
[TBL] [Abstract][Full Text] [Related]
29. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Polyzos SA; Goulis DG; Kountouras J
Ann Hepatol; 2015; 14(6):941-3. PubMed ID: 26436371
[No Abstract] [Full Text] [Related]
30. Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome.
Tock L; Carneiro G; Togeiro SM; Hachul H; Pereira AZ; Tufik S; Zanella MT
Endocr Pract; 2014 Mar; 20(3):244-51. PubMed ID: 24246334
[TBL] [Abstract][Full Text] [Related]
31. Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.
Tantanavipas S; Vallibhakara O; Sobhonslidsuk A; Phongkitkarun S; Vallibhakara SA; Promson K; Sophonsritsuk A
Biomed Res Int; 2019; 2019():9047324. PubMed ID: 31467918
[TBL] [Abstract][Full Text] [Related]
32. Comment on "dairy protein intake is inversely related to development of non-alcoholic fatty liver disease".
Nadeem A; Kumar S
Clin Nutr; 2022 Jun; 41(6):1459-1460. PubMed ID: 35501210
[No Abstract] [Full Text] [Related]
33. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome.
Chakraborty S; Ganie MA; Masoodi I; Jana M; ; Gupta N; Sofi NY
Indian J Med Res; 2020 Apr; 151(4):333-341. PubMed ID: 32461397
[TBL] [Abstract][Full Text] [Related]
34. A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease.
Dawson AJ; Sathyapalan T; Smithson JA; Vince RV; Coady AM; Ajjan R; Kilpatrick ES; Atkin SL
Clin Endocrinol (Oxf); 2014 Jun; 80(6):843-9. PubMed ID: 23746214
[TBL] [Abstract][Full Text] [Related]
35. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Asfari MM; Sarmini MT; Baidoun F; Al-Khadra Y; Ezzaizi Y; Dasarathy S; McCullough A
BMJ Open Gastroenterol; 2020 Aug; 7(1):. PubMed ID: 32784205
[TBL] [Abstract][Full Text] [Related]
36. Duodenal-jejunal bypass improves nonalcoholic fatty liver disease independently of weight loss in rodents with diet-induced obesity.
Angelini G; Castagneto-Gissey L; Casella-Mariolo J; Caristo ME; Russo MF; Lembo E; Verrastro O; Stefanizzi G; Marini PL; Casella G; Bornstein SR; Rubino F; Mingrone G
Am J Physiol Gastrointest Liver Physiol; 2020 Oct; 319(4):G502-G511. PubMed ID: 32812775
[TBL] [Abstract][Full Text] [Related]
37. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis.
Sarkar M; Terrault N; Chan W; Cedars MI; Huddleston HG; Duwaerts CC; Balitzer D; Gill RM
Liver Int; 2020 Feb; 40(2):355-359. PubMed ID: 31627243
[TBL] [Abstract][Full Text] [Related]
38. Long-term androgen excess induces insulin resistance and non-alcoholic fatty liver disease in PCOS-like rats.
Cui P; Hu W; Ma T; Hu M; Tong X; Zhang F; Shi J; Xu X; Li X; Shao LR; Billig H; Feng Y
J Steroid Biochem Mol Biol; 2021 Apr; 208():105829. PubMed ID: 33513383
[TBL] [Abstract][Full Text] [Related]
39. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Dawson AJ; Kilpatrick ES; Coady AM; Elshewehy AMM; Dakroury Y; Ahmed L; Atkin SL; Sathyapalan T
BMC Endocr Disord; 2017 Jul; 17(1):41. PubMed ID: 28705172
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.
Bohdanowicz-Pawlak A; Lenarcik-Kabza A; Brona A; Kuliczkowska-Płaksej J; Łaczmański Ł; Zaleska-Dorobisz U; Milewicz A
Endokrynol Pol; 2014; 65(6):416-21. PubMed ID: 25554608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
